Literature DB >> 8414413

Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study.

J D Gass1, B A Blodi.   

Abstract

BACKGROUND: Idiopathic juxtafoveolar retinal telangiectasis may cause visual loss. The treatment of this disease is controversial.
METHODS: The authors reviewed the records of 140 patients with idiopathic juxtafoveolar telangiectasis. A classification scheme based on biomicroscopic and fluorescein angiographic findings is presented. In addition, the effect of photocoagulation on the natural history of the disorder is evaluated.
FINDINGS: Patients are categorized into three groups. Group 1 comprises 39 male patients with nonfamilial, easily visible telangiectasis and intraretinal exudation. The telangiectasis is unilateral in 94% of patients. The telangiectasia in this group is probably of developmental origin (Coats syndrome). Group 2 comprises 94 patients with occult juxtafoveolar telangiectasis, minimal exudation, superficial retinal crystalline deposits, and right-angle venules. Late in the course of the disease, foveolar atrophy, intraretinal pigment plaques, and subretinal neovascularization develop. The telangiectasis is acquired during middle age and is bilateral in 98% of patients. Group 3 comprises seven patients with bilateral easily visible telangiectasis, minimal exudation, and capillary occlusion. All of these patients had systemic disease, which was probably related to their eye disease.
CONCLUSION: Slow visual loss beginning in adulthood characterizes most of these patients. The telangiectasis appears to be caused primarily by retinal capillary leakage in group 1, capillary diffusion abnormalities in group 2, and capillary occlusion in group 3. Photocoagulation is probably beneficial for patients in group 1 and not for patients in group 2, at least before their development of subretinal neovascularization.

Entities:  

Mesh:

Year:  1993        PMID: 8414413

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  129 in total

1.  Clinical-pathologic correlation in Coats' disease.

Authors:  J B Jonas; L M Holbach
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-07       Impact factor: 3.117

2.  Idiopathic parafoveal telangiectasis associated with a foveal pseudovitelliform lesion.

Authors:  E Margalit; R S Apte; S R Sadda
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

3.  Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.

Authors:  Brian C Toy; Euna Koo; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

4.  Retinal crystals in type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Irene Leung; Mina Chung; Ute E K Wolf-Schnurrbusch; Alfredo Dubra; David R Williams; Traci Clemons; Daniel Pauleikhoff; Alan C Bird; Tunde Peto
Journal:  Ophthalmology       Date:  2011-08-12       Impact factor: 12.079

5.  Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Authors:  Buğra Karasu; Betul Onal Gunay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-25       Impact factor: 3.117

6.  Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins.

Authors:  Shabeeba R Hannan; Krishnappa C Madhusudhana; Christina Rennie; Andrew J Lotery
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

7.  Staging of macular telangiectasia: power-Doppler optical coherence tomography and macular pigment optical density.

Authors:  Eric K Chin; Dae Yu Kim; Allan A Hunter; Suman Pilli; Machelle Wilson; Robert J Zawadzki; John S Werner; Susanna S Park
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-02       Impact factor: 4.799

8.  Retinal vascular density evaluated by optical coherence tomography angiography in macular telangiectasia type 2.

Authors:  Berna Dogan; Muhammet Kazim Erol; Melih Akidan; Elcin Suren; Yusuf Akar
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

9.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-29       Impact factor: 4.799

10.  Bevacizumab in the treatment of idiopathic macular telangiectasia.

Authors:  Maria-Andreea Gamulescu; Andreas Walter; Helmut Sachs; Horst Helbig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.